209 related articles for article (PubMed ID: 20649825)
1. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Tanaka Y; Masumori N; Tsukamoto T
Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W
Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089
[TBL] [Abstract][Full Text] [Related]
5. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study].
Kalchthaler M; Mühlich S; Rothe P
MMW Fortschr Med; 2011 Jan; 152 Suppl 4():119-24. PubMed ID: 21598462
[No Abstract] [Full Text] [Related]
7. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
Neĭmark AI; Riapolova MV; Mel'nik MA
Urologiia; 2010; (2):36-8. PubMed ID: 20967993
[TBL] [Abstract][Full Text] [Related]
8. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
[TBL] [Abstract][Full Text] [Related]
11. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T
Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651
[TBL] [Abstract][Full Text] [Related]
12. [Overactive bladder. When it's pressing, immediate help is indicated].
Widhalm S
MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642
[No Abstract] [Full Text] [Related]
13. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M;
Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248
[TBL] [Abstract][Full Text] [Related]
15. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary.
Yokoyama O; Yamaguchi O; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; Yamada S
J Urol; 2011 Jul; 186(1):170-4. PubMed ID: 21575976
[TBL] [Abstract][Full Text] [Related]
17. Solifenacin.
Kreder KJ
Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
[TBL] [Abstract][Full Text] [Related]
18. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
19. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S
Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]